anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The present invention relates to antibodies that bind to the A chain N-terminal peptide. The present invention also relates to (1) a polypeptide containing the same or substantially the same amino acid sequence as the amino acid sequence represented by SEQ ID NO:7 (A chain), (2) a polypeptide containing the same or substantially the same amino acid sequence as the amino acid sequence represented by SEQ ID NO:8 (B chain), (3) a polypeptide wherein the A and B chains are bonded to each other via disulfide bonds (2 chains) or its salt., (4) DNAs encoding the same, etc. These polypeptides and DNAs encoding the same can be used for the diagnosis, treatment, prevention, etc. for diseases, including abnormalities (e.g., diabetes mellitus, etc.) in metabolic regulation (sugar metabolism, lipid metabolism, etc.) of energy sources such as carbohydrates.
OBJECTIVES: Urea and creatinine concentrations in plasma are used to guide hemodialysis (HD) in patients with end-stage renal disease (ESRD). To support individualized HD treatment in a home situation, there is a clinical need for a non-invasive and continuous alternative to plasma for biomarker monitoring during and between cycles of HD. In this observational study, we therefore established the correlation of urea and creatinine concentrations between sweat, saliva and plasma in a cohort of ESRD patients on HD.
METHODS: Forty HD patients were recruited at the Dialysis Department of the Catharina Hospital Eindhoven. Sweat and salivary urea and creatinine concentrations were analyzed at the start and at the end of one HD cycle and compared to the corresponding plasma concentrations.
RESULTS: A decrease of urea concentrations during HD was observed in sweat, from 27.86 mmol/L to 12.60 mmol/L, and saliva, from 24.70 mmol/L to 5.64 mmol/L. Urea concentrations in sweat and saliva strongly correlated with the concentrations in plasma (ρ 0.92 [p<0.001] and 0.94 [p<0.001], respectively). Creatinine concentrations also decreased in sweat from 43.39 μmol/L to 19.69 μmol/L, and saliva, from 59.00 μmol/L to 13.70 μmol/L. However, for creatinine, correlation coefficients were lower than for urea for both sweat and saliva compared to plasma (ρ: 0.58 [p<0.001] and 0.77 [p<0.001], respectively).
CONCLUSIONS: The results illustrate a proof of principle of urea measurements in sweat and saliva to monitor HD adequacy in a non-invasive and continuous manner. Biosensors enabling urea monitoring in sweat or saliva could fill in a clinical need to enable at-home HD for more patients and thereby decrease patient burden.
Methods for producing cellulose articles having controlled release of active ingredient include dispersing pulp in aqueous direct solvent for cellulose to form a slurry. Organically modified or ion-exchange-activated phyllosilicate is homogenized in a direct solvent for cellulose with exfoliation by shearing, then mixed with the slurried pulp. A mixture of active ingredient and a lipophilic matrix material or a water-in-oil (“W/O”) emulsion containing active ingredient is stabilized with thickener, converted into a gel-like paste, and mixed with the slurried pulp. Water is stripped from the mixture until all cellulose is dissolved, the mixture is formed into shaped articles, and dried. Exemplary active ingredients include cosmetic active ingredients, fat-soluble vitamins or apolar plant extracts. Domains of active ingredient and matrix material or emulsion containing active ingredient are present as fine divisions within the inventive articles. Exemplary shaped articles include functional fibers in knitted, woven and nonwoven fabrics; paper; foils and membranes.
PURPOSE: A tumor-specific promoter, an oncolytic virus vector, and a pharmaceutical composition containing the same are provided to ensure an excellent oncolytic effect to tumor cells and to treat cancer. CONSTITUTION: A tumor-specific promoter has a nucleotide sequence of sequence number 8 or 10. The tumor-specific promoter is inserted into the nucleotide sequence of sequence number 8 or 10, and is linked to the nucleotide. The tumor-specific promoter additionally contains an additional nucleotide sequence with tumor-specific promoter activity. The additional nucleotide sequence is an exogenous promoter. A nucleic acid construct contains the tumor-specific promoter and a foreign gene which is operably linked to the tumor-specific promoter. A pharmaceutical composition for treating cancer contains a virus expression vector containing the nucleic acid construct and a pharmaceutically acceptable carrier.
The colloid osmotic effect of ALBUMIN (HUMAN) 20% and 25% is approximately 5 times the volume administered. When injected intravenously, it will increase circulating plasma volume by approximately 3.5 times the volume infused within 15 minutes if the patient is adequately hydrated. This extra fluid reduces hemoconcentration and blood viscosity. The degree and duration of volume expansion depends upon the initial blood volume. When treating patients with diminished blood volume, the effect of infused albumin may persist for many hours. The hemodilution lasts for a shorter time when albumin is administered to individuals with normal blood volume. [ 4 ]
Pharmacokinetic parameters of rFVIII measured in subset of 10 participants, consisting of:18 Years to 65 Years. In Part 1 of the study, subjects received a single intravenous infusion of 50 IU/kg rFVIII preceded by a 72 hours washout period.
To provide cells expressing a chimeric antigen receptor (CAR) that can recognize a ligand, for example, a soluble ligand.SOLUTION: The invention provides a cell including a first chimeric antigen receptor (CAR) and a second CAR, where the first and second CARs bind to different epitopes on the same ligand. The cell can be used in a method for treating diseases such as cancer. The ligand may be a soluble ligand. The ligand may be a cytokine, chemokine or metabolite. The respective CARs may comprise: (i) an antigen-binding domain; (ii) a spacer; and (iii) a transmembrane domain. The spacers of the first and second CARs may be different.SELECTED DRAWING: None
OBJECTIVE: Household chaos, defined as a lack of organization, structure, and predictability, has been linked to deleterious childhood health outcomes and may hinder attempts to initiate and maintain healthy lifestyle changes. This study examined the associations of household chaos and obesity-related health conditions in a sample of youth being treated for obesity.
METHODS: Participants were 715 patients (61.8% girls; Mage = 12.3 years; 68.7% non-Hispanic Black; M% of 95th BMI %-ile = 146.9%) enrolled in a pediatric weight management clinic. Caregiver report of household chaos was measured using the Confusion, Hubbub and Order Scale (CHAOS). Physiological obesity-related comorbidities (e.g., insulin resistance, hypertension, dyslipidemia) were assessed by a medical clinician and abstracted from electronic medical records; health conditions were dichotomized as present or not present. Psychological functioning was measured with the Pediatric Symptom Checklist, a caregiver-completed mental health screen that assesses internalizing, externalizing, and attention concerns.
RESULTS: The Wilcoxon rank-sum test was used to test differences in household chaos scores for each obesity-related health condition. Caregivers of youth diagnosed with hypertension and obstructive sleep apnea reported significantly lower levels of household chaos, while caregivers who reported clinical levels of psychological dysfunction reported higher levels of chaos.
CONCLUSIONS: Traditional management of childhood obesity requires changes across multiple health domains (e.g., dietary, exercise, sleep), and such change may be facilitated by structure and consistency. Present findings suggest that psychological resources within pediatric weight management settings should address individual patient-level factors associated with physiological and mental health as well as household functioning.
Patients with a planned RYGB at UZ Leuven will be recruited. Iron supplements, more specific Ferrodyn and Vista Ferrum will be administrated in these patients before and 1, 3, 6 and 12 months post-RYGB with at least 7 days between the administration of the different supplements.
In infectious disease models, it is known that mechanisms such as births, seasonality in transmission and pathogen evolution can generate oscillations in infection numbers. We show how waning immunity is also a mechanism that is sufficient on its own to enable sustained oscillations. When previously infected or vaccinated individuals lose full protective immunity, they become partially susceptible to reinfections. This partial immunity subsequently wanes over time, making individuals more susceptible to reinfections and potentially more infectious if infected. Losses of full and partial immunity lead to a surge in infections, which is the precursor of oscillations. We present a discrete-time Susceptible-Infectious-Immune-Waned-Infectious (SIRWY) model that features the waning of fully immune individuals (as a distribution of time at which individuals lose fully immunity) and the gradual loss of partial immunity (as increases in susceptibility and potential infectiousness over time). A special case of SIRWY is the discrete-time SIRS model with geometric distributions for waning and recovery. Its continuous-time analogue is the classic SIRS with exponential distributions, which does not produce sustained oscillations for any choice of parameters. We show that the discrete-time version can produce sustained oscillations and that the oscillatory regime disappears as discrete-time tends to continuous-time. A different special case of SIRWY is one with fixed times for waning and recovery. We show that this simpler model can also produce sustained oscillations. In conclusion, under certain feature and parameter choices relating to how exactly immunity wanes, fluctuations in infection numbers can be sustained without the need for any additional mechanisms.
<P>PROBLEM TO BE SOLVED: To inhibit or prevent unchecked growth of cancer cells, or to stimulate differentiation of the cancer cells.  <P>SOLUTION: The invention provides methods for alleviating symptoms of cancer by administering a morphogen. The present invention also provides compositions and methods for inhibition or prevention of unchecked growth of the cancer cells or for stimulation of differentiation of the cancer cells. The invention is an approach other than methods currently used for treating cancers and alleviating symptoms thereof. The methods of the present invention also decrease side effects which are representatively observed with conventional chemotherapies for treatment of the cancers.  <P>COPYRIGHT: (C)2010,JPO&INPIT
BACKGROUND: Anaemia is a severe and common complication in patients with aneurysmal subarachnoid haemorrhage (aSAH). Early intervention for at-risk patients before anaemia occurs is indicated as potentially beneficial, but no validated method synthesises patients' complicated clinical features into an instrument. The purpose of the current study was to develop and externally validate a nomogram that predicted postacute phase anaemia after aSAH.
METHODS: We developed a novel nomogram for aSAH patients to predict postacute phase anaemia (3 days after occurrence of aSAH, prior to discharge) on the basis of demographic information, imaging, type of treatment, aneurysm features, blood tests and clinical characteristics. We designed the model from a development cohort and tested the nomogram in external and prospective validation cohorts. We included 456 aSAH patients from The First Affiliated Hospital for the development, 220 from Sanmen People's Hospital for external validation and a prospective validation cohort that included 13 patients from Hangzhou Red Cross Hospital. We assessed the performance of the nomogram via concordance statistics and evaluated the calibration of predicted anaemia outcome with observed anaemia occurrence.
RESULTS: Variables included in the nomogram were age, treatment method (open surgery or endovascular therapy), baseline haemoglobin level, fasting blood glucose level, systemic inflammatory response syndrome score on admission, Glasgow Coma Scale score, aneurysm size, prothrombin time and heart rate. In the validation cohort, the model for prediction of postacute phase anaemia had a c-statistic of 0.910, with satisfactory calibration (judged by eye) for the predicted and reported anaemia outcome. Among forward-looking forecasts, our predictive model achieved an 84% success rate, which showed that it has some clinical practicability.
CONCLUSIONS: The developed and validated nomogram can be used to calculate individualised anaemia risk and has the potential to serve as a practical tool for clinicians in devising improved treatment strategies for aSAH.
The present invention relates to a compound formula patent medicine which takes Tibet herba artemisiae as main medicine and is characterized in that (1). the formula is prepared from the following raw materials, such as 5 to 60% of Tibet herba artemisiae, 4.5 to 60 % of bupleurum root, 10 to 88% of barbary wolfberry fruit, 1 to 80% of safflower and 0.5 to 25% of radix glycyrrhiza, and the proportion is the weight percentage of dry matters; (2). the medicinal materials according to the formula can be prepared into capsules, tablets, oral medicinal liquid, etc. and other forms. The patent medicine of the present invention has obvious treating effects on viral hepatitis A, viral hepatitis B, viral hepatitis C, viral hepatitis D, viral hepatitis E, acute icteric hepatitis and chronic persistent hepatitis; the total effective rate of various kinds of viral hepatitis is 89%, the cure rate is 80.8%, and the effective rate of the chronic persistent hepatitis is above 90%. The prescription has the advantages of fair formula, wide source of medicinal materials and no toxic or side effect, and is the new medical breakthrough for treating the hepatitis.
Method of producing a refracting anticorrosion protection layer on metallic dental material which is susceptible to hot corrosion comprises gas phase  to produce a ceramic material at a residual pressure of 5-20 mbar and 900-1000 deg.C. The ceramic is produced from a cpd. of a metalloid e.g. B, C, Si, N, O2 with a metal and/or further metalloid.  The metal is Al (except when used together with Si) and/or transition metal(s) including the lanthanides. ADVANTAGE - Coating protects the dental material e.g. Ti (alloy) from hot corrosion. A layer between the framework and the Ti also prevents ion diffusion which would lead to discolouration.
PURPOSE:To provide a foamable bathing agent containing a carbonate and an acid, producible at a low cost, having excellent stability when mixed with a carbonate and capable of dissolving a large amount of carbon dioxide gas in bath water to promote the hot spring effect of the bath, by using adipic acid as the acid. CONSTITUTION:The objective foamable bathing agent contains a carbonate such as sodium bicarbonate, sodium carbonate, sodium sesquicarbonate, etc., and adipic acid as essential components. The cost of the acid accounting for the major part of the total cost of the agent is reduced in the present agent. The carbonate can be mixed stably with the acid without causing the decomposition of the carbonate, and the agent generates a large amount of carbon dioxide gas slowly in bath water. The sum of both components is 50-100wt% of the whole bathing agent and the ratio of the components is selected to complete the reaction without causing the excess and deficiency of the component. However, it is preferable to use the acid in excess to some extent to promote the dissolution of the generated carbon dioxide gas in bath water.
PROBLEM TO BE SOLVED: To incorporate a therapeutic drug into a polymetric layer of an inner layer in a blood vessel upon implantation without interfering a stent function by forming the therapeutic drug to include particles having a predetermined maximum cross-sectional dimension, and by uniformly dispersing the therapeutic drug particles to be a predetermined percentage of whole weight of the therapeutic drug particles and the polymetric material. SOLUTION: A therapeutic drug having a maximum cross-sectional dimension of about 10 microns, such as heparin particles, is formed preferably by air milling from a crystal of the therapeutic drug. The therapeutic drug particles are uniformly dispersed by using an extruding device 10 into the polymetric material such as polycaprolactam which is adapted for the stent within the blood vessel. At this time, the therapeutic drug particles are kept within 70 wt.% of the whole weight of the therapeutic drug and the polymetric material. And porosigen can be added if it is required. The extruding device 10 has a load screw 14, and a barrel 16 is covered with a thermostat heater 18 and preferably heated thereby.
The purpose of this study is to better understand genetic susceptibility to melanoma and the interactions of specific polymorphisms with each other and with environmental factors.

To accomplish this, buccal swabs or blood specimens from patients with melanoma (either single primary or multiple primary) have been collected. Specimens will be prepared in the Epidemiology Laboratory at MSKCC. They will be analyzed at MSKCC for INK4A (and functional assays for DNA repair capacity when blood is available) and the melanocortin gene (MC1R), at the University of North Carolina for polymorphisms in DNA repair genes and immune function genes, at the University of Pennsylvania for polymorphisms in the melanocortin receptor gene (MC1R) and immune function genes, and at the University of California (Irvine) for polymorphisms in metabolizing genes (P450's and GST's). Samples will be banked at MSKCC and the University of New Mexico. In order to perform this study, subjects from population-based registries in the United States (New Jersey, North Carolina, Michigan, San Diego/Imperial Counties), Canada (Cancer Care Ontario, British Columbia), Italy (Turin), Australia (New South Wales, Tasmania), were interviewed, asked to provide blood or buccal swab samples and asked to provide permission to obtain and review slides of their primary melanoma. This study is now closed to accrual.
The emergence of electronic smoking devices is a recent and scientifically underexplored phenomenon. These devices were initially thought of as a harm-reduction strategy in cigarette smokers, a purpose for which there is still no definitive evidence of effectiveness. Preliminary but consistent findings in the literature suggest the possibility of detrimental health effects to e-cigarette users. Despite being prohibited for sale in the country, electronic cigarettes are easily accessible, in an unregulated manner. The increasing number of users, approaching one million according to recent data, and the uncertainties regarding the composition, manufacturing quality, and potential long-term effects of exposure to the vapor they produce, make the use of electronic cigarettes an emerging issue in Brazilian public health. Based on the aforementioned issues, exploring the potential effects of this new health-related behavior is urgent. Thus, the present proposal describes a research project envisioning the execution of two interconnected studies: (1) an observational cross-sectional analysis, in an exposed-control design, evaluating general health parameters of electronic cigarette users compared to non-smoking control individuals, matched by sex and age; and (2) an intervention study nested within the first study, designed as a randomized clinical trial, with electronic cigarette users assigned to a group that will take a 7-day pause from using these devices, compared to a control group that will not undergo any intervention. The studies were designed with cardiorespiratory fitness - measured by a maximum exercise cardiopulmonary test (ergospirometry) - as the primary outcome. The sample size calculated for the cross-sectional study comprises 148 individuals (74 per group), and the intended sample for the randomized clinical trial consists of the 74 electronic cigarette users already recruited for the cross-sectional study. The secondary outcomes of both studies are related to cardiorespiratory parameters, pulmonary function (spirometry), vascular function (endothelial function and tissue oxygenation), cardiovascular risk (lipid profile and blood pressure), inflammatory markers, and anthropometric measurements. The statistical analyses will be performed using Analysis of Covariance (ANCOVA), with physical activity level as a covariate for the cross-sectional study, and Generalized Estimating Equations (GEE), with initial oxygen consumption value as a covariate for the clinical trial. The investigators expect that the proposed studies yield new and relevant information regarding the potential harmful effects of electronic cigarettes, as well as the possibility of reversing these effects through refraining from their consumption. The novelty of the studies, the urgency of the topic, the boldness of the experimental approaches, and the high immediate applicability of the findings are highlighted in this proposal, with the potential to support public health policies concerning this relevant issue.
PURPOSE:To obtain hydrogel having excellent mechanical strengths by lowering underwater swellability and flexibility of frozen PVA gel, by repeating the freeze-thaw operation of a specified aq. PVA soln. at least twice. CONSTITUTION:An aq. soln. contg. 6-25wt% PVA having a saponification degree of 95mol% or above and an average degree of polymn. of 70 or above is charged in a container having an arbitrary shape or a molding die, molded by cooling it to -3 deg.C or lower at a cooling rate of 0.1-7 deg.C/min or 7-1,000 deg.C/min, thawed at a thawing rate of 1-3 deg.C/min or 3-1,000 deg.C/min to 55 deg.C or lower by allowing it to stand, and then frozen. This operation is repeated at least twice. EFFECT:The obtained hydrogel has a good shape retention, i.e., it exhibits a high elasticity despite its high moisture content and can restore its original shape, when pressed, even though it is temporarily deformed.
This arm will not receive active photobiomodulation (PBM). Instead, they will use a sham Vielight Neuro Gamma device, once every other day (e.g., Mon, Wed, Fri) for 20 minutes for 16 weeks.
Study participation will consist of tests of memory and thinking, a MRI, and two PET scans. F-18 FDG and C-11 Pittsburgh compound B (PiB) are two drugs used in PET scans.
PURPOSE OF REVIEW: In this review, we aim to summarize the impact of surgical complications and adverse events on surgeons, including psychiatric illnesses. We evaluate current programs to develop trainee well-being and investigate research within the field of urology.
RECENT FINDINGS: Surgical complications and adverse events affect all surgeons, including surgical trainees. Research estimates that 80% of healthcare professionals have been involved in an event that affected them emotionally. These events can affect physicians in many ways, ranging from negatively impacting their quality of life to leading to psychiatric disorders such as acute stress reactions and post-traumatic stress disorder. Unfortunately, there is no standardized preparation to equip trainees to manage and rebound from the profound emotional impact of surgical complications. Data in this realm is insufficient, especially in urology, and we need more research in order to better evaluate emotional implications of complications on trainees and how we can prepare trainees to handle them.
COGPACK is a computer-based neuropsychological cognitive training program. It will be administered by a trainer in an open group of 6- 8 patients. Sessions will take place twice a week, and each session will last 45 - 60 minutes.